Profile data is unavailable for this security.
About the company
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
- Revenue in USD (TTM)1.70m
- Net income in USD-208.38m
- Incorporated2018
- Employees463.00
- LocationAutolus Therapeutics PLCThe Mediaworks, 191 Wood LaneLONDON W12 7FPUnited KingdomGBR
- Phone+44 203 829 6230
- Websitehttps://www.autolus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liquidia Corp | 17.49m | -78.50m | 952.63m | 136.00 | -- | 18.18 | -- | 54.47 | -1.21 | -1.21 | 0.2691 | 0.6891 | 0.1413 | -- | 3.85 | 128,588.20 | -63.43 | -55.02 | -71.31 | -62.69 | 83.49 | 82.18 | -448.89 | -474.59 | -- | -26.14 | 0.4942 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Innoviva Inc | 310.46m | 179.72m | 964.85m | 112.00 | 6.80 | 1.43 | 4.48 | 3.11 | 2.24 | 2.24 | 3.96 | 10.66 | 0.2509 | 0.8825 | 4.19 | 2,771,991.00 | 14.52 | 26.24 | 15.62 | 28.53 | 86.27 | -- | 57.89 | 76.84 | 7.96 | -- | 0.398 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Cassava Sciences Inc | 0.00 | -97.22m | 966.11m | 29.00 | -- | 6.86 | -- | -- | -2.32 | -2.32 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -50.31 | -30.74 | -53.23 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 59.61m | -262.14m | 973.59m | 296.00 | -- | 9.25 | -- | 16.33 | -3.90 | -3.90 | 0.8602 | 0.9161 | 0.1508 | 0.483 | 3.48 | 201,371.60 | -66.31 | -65.64 | -74.24 | -71.72 | 91.63 | -- | -439.79 | -1,513.03 | 6.80 | -8.11 | 0.6947 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Silence Therapeutics plc | 35.02m | -53.23m | 1.00bn | 116.00 | -- | 37.16 | -- | 28.69 | -0.4891 | -0.4891 | 0.3211 | 0.2153 | 0.2527 | -- | 94.73 | 301,901.80 | -38.40 | -43.18 | -47.88 | -53.35 | 54.24 | -- | -151.98 | -422.12 | -- | -15.11 | 0.0155 | -- | 40.97 | 305.31 | -2.74 | -- | 149.02 | -- |
| Autolus Therapeutics PLC (ADR) | 1.70m | -208.38m | 1.06bn | 463.00 | -- | -- | -- | 626.45 | -1.20 | -1.20 | 0.0098 | -- | 0.0039 | -- | 14.77 | 3,667.39 | -48.14 | -42.32 | -53.81 | -46.61 | -- | -- | -12,272.26 | -5,098.00 | -- | -6.06 | 0.00 | -- | -73.30 | -- | -40.01 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 1.09bn | 85.00 | -- | 2.39 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| AbCellera Biologics Inc | 38.03m | -146.40m | 1.10bn | 586.00 | -- | 0.949 | -- | 28.95 | -0.5062 | -0.5062 | 0.1315 | 3.96 | 0.0251 | -- | 1.10 | 64,890.79 | -9.67 | 6.08 | -10.49 | 6.67 | -- | -- | -384.99 | 24.69 | 7.32 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Vir Biotechnology Inc | 86.18m | -615.06m | 1.12bn | 587.00 | -- | 0.6975 | -- | 12.97 | -4.59 | -4.59 | 0.6425 | 11.80 | 0.0365 | -- | -- | 146,814.30 | -26.06 | -0.6081 | -30.49 | -0.7192 | 96.79 | -- | -713.76 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Prothena Corporation PLC | 91.37m | -147.03m | 1.12bn | 173.00 | -- | 2.00 | -- | 12.27 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Scholar Rock Holding Corp | 0.00 | -165.79m | 1.13bn | 150.00 | -- | 4.90 | -- | -- | -1.99 | -1.99 | 0.00 | 2.96 | 0.00 | -- | -- | 0.00 | -49.55 | -38.14 | -55.26 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.1817 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| MannKind Corp | 198.96m | -11.94m | 1.14bn | 414.00 | -- | -- | -- | 5.75 | -0.0464 | -0.0464 | 0.7087 | -0.9116 | 0.5165 | 2.50 | 12.55 | 480,584.50 | -3.10 | -26.07 | -3.99 | -37.80 | 68.45 | 59.68 | -6.00 | -57.61 | 3.31 | 0.5023 | 1.90 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Mirum Pharmaceuticals Inc | 186.37m | -163.42m | 1.15bn | 264.00 | -- | 4.60 | -- | 6.17 | -4.08 | -4.08 | 4.56 | 5.32 | 0.3729 | 3.37 | 4.05 | 705,962.10 | -32.70 | -38.93 | -38.55 | -44.88 | 74.76 | -- | -87.68 | -190.71 | 4.19 | -79.67 | 0.552 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.18bn | 20.00 | -- | 12.81 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 1.18bn | 355.00 | -- | 3.36 | -- | 7.25 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
Data as of Apr 26 2024. Currency figures normalised to Autolus Therapeutics PLC's reporting currency: US Dollar USD
32.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Syncona Investment Management Ltd.as of 31 Dec 2023 | 21.35m | 8.03% |
| Qatar Investment Authority (Investment Management)as of 09 Dec 2022 | 15.00m | 5.64% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 12.61m | 4.74% |
| Deep Track Capital LPas of 31 Dec 2023 | 11.87m | 4.46% |
| TFG Asset Management UK LLPas of 31 Dec 2023 | 8.00m | 3.01% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 5.45m | 2.05% |
| Armistice Capital LLCas of 31 Dec 2023 | 3.85m | 1.45% |
| Adage Capital Management LPas of 31 Dec 2023 | 3.83m | 1.44% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.00m | 1.13% |
| J.O. Hambro Capital Management Ltd.as of 31 Mar 2024 | 2.23m | 0.84% |
More ▼
Data from 31 Dec 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
